SRPT news · SRPT stock

Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?

Yahoo Finance · Aug 24, 2026 · Sarepta Therapeutics Inc (SRPT)

Keros' rinvatercept pipeline offers upside, but zero quarterly revenue, clinical risk and a premium valuation make the stock a cautious bet.

Original at Yahoo Finance

Not investment advice. Cached headline, not a full reprint.